INTRODUCTION
Systemic lupus erythematosus (SLE) is an autoimmune syndrome characterized by the formation of autoantibodies to nuclear components, immune complex deposition, and inflammatory-cell-mediated organ damage. Significant progress has been made over the last decade describing the putative role of innate immune processes in disease pathogenesis. These abnormalities include stimulation of Toll-like receptor (TLR) signaling by immune complexes, activation of persistent type I interferon (IFN) responses, and hyperproduction of neutrophil extracellular traps (NETs) [1] [2] [3] [4] . In the last few years, another innate immune signaling complex, the inflammasome, has garnered support for a role in promoting organ damage and contributing to the SLE phenotype. This review will discuss the recent evidence that implicates the inflammasome in SLE pathogenesis.
THE INFLAMMASOME
The inflammasome is a multimolecular complex that, when induced to oligomerize, results in the activation of caspase-1, the primary enzyme responsible for the activation of the proinflammatory cytokines IL-1b and IL-18 (reviewed in [5] ). Activation of the inflammasome, particularly in the context of intracellular infections, may also result in an inflammatory form of cell death dependent on caspase-1, termed pyroptosis [6] . Most inflammasomes involve a NOD-like receptor (NLR), such as NLRP3, which contains a C-terminal leucine-rich repeat domain, a central NACHT nucleotide-binding domain, and an N-terminal PYRIN domain, which is able to interact with the PYRIN domain of the adaptor Apoptosisassociated speck-like protein containing a CARD (ASC). ASC is able to recruit caspase-1 via its CARD domain resulting in oligomerization of multiple caspase-1 molecules that, in turn, cleave and activate each other (reviewed in [7] ). Other inflammasomes are formed from scaffolds not related to the NLR family. These include Absent in Melanoma 2 (AIM2), IFN-g inducible protein 16 (IFI16), and retinoic acid inducible gene I (RIG-I). These proteins are able to assemble inflammasomes in response to cytosolic nucleic acids. They also play important roles in the induction of antiviral type I IFN responses. How the cytokine activation and IFNregulating roles of non-NLR inflammasomes are regulated is still an area of investigation [7] .
Regulation of inflammasome activity occurs at multiple levels. NLRP3 and IL-1b are not constitutively expressed. They require a 'priming' step, usually stimulation by TLR ligands, which subsequently activate NFkB and their transcription [8] . Deubiquitination of NLRP3 has also been reported as an important intermediate step for inflammasome priming [9] . Final activation of the inflammasome depends on the presence of unique ligands or cellular metabolic changes that result in assembly of the complex. These include stimuli as diverse as bacterial peptidoglycans, nucleic acids, and various crystals [10] [11] [12] .
The inflammasome is a recognized central pathogenic player in several rheumatologic diseases. The inherited cryopyrinopathies stem from activating mutations in NLRP3, leading to increased IL-1b production [13] . Gout and pseudogout involve joint inflammation secondary to the activation of the NLRP3 inflammasome by monosodium urate and calcium pyrophosphate crystals, respectively [12] . Research is also ongoing into the role of the inflammasome in diseases such as inflammatory bowel disease, type II diabetes, and metabolic syndrome [14] [15] [16] . Importantly, a role for inflammasome in SLE pathogenesis is emerging (Table 1) .
KEY POINTS
Activation of the inflammasome by SLE-specific immune complexes, complement activation, or neutrophil NETs may contribute to organ inflammation and propagation of aberrant immune responses.
Inhibition of NLRP3, caspase-1, and IL-18 has shown benefit to nephritis in various murine models of lupus.
Activation of caspase-1 contributes to endothelial progenitor cell dysfunction and may promote vascular damage in SLE. [17] . The same polymorphisms in this gene are also highly associated with the development of SLE and correlate with the phenotypes of nephritis, arthritis, and cutaneous lesions [18] . These polymorphisms lead to increased IL-1b production from circulating monocytes [19] . Other inflammasome genes, including NLRP3, AIM2, NLRC4, and CASP1, were not associated with increased risk for SLE in the same study [18] . The role of genetic polymorphisms in the cytokines activated by the inflammasome has also been examined. Several polymorphisms in the promoter of IL-18 have been related to increased risk of SLE in several different ethnic populations [20
Despite several studies [18, 22] , no convincing evidence for IL-1b polymorphisms contributing to SLE risk has been documented.
ACTIVATION OF THE INFLAMMASOME IN SYSTEMIC LUPUS ERYTHEMATOSUS
Increased expression of inflammasome components, including NLRP3 and caspase-1, has been reported in lupus nephritis biopsies [23] , suggesting that this tissue may be primed for inflammasome activation. How the inflammasome is triggered in SLE is an important concept for understanding its role in this disease. Immune complexes formed secondary to antibody recognition of DNA or RNA antigens have been shown to stimulate inflammasome activation through upregulation of TLRdependent activation of NFkB and subsequent activation of the NLRP3 inflammasome [24,25 && ]. Importantly, the use of chloroquine, an antimalarial that interferes with TLR7 and TLR9 activation in the lysosomal compartment, is able to block the stimulation of IL-1b release following stimulation of monocytes with RNA or DNA immune complexes [24,25 && ]. C3a, which is released during complement activation in tissues, promotes inflammasome activation through upregulation of ATP secretion [26 & ]. Together, these results support the notion that immune complex deposition and complement consumption in organs affected by SLE promote activation of the inflammasome and may contribute to organ damage through this mechanism.
NETs have also been proposed to play a pathogenic role in SLE. These structures are released spontaneously by a subset of proinflammatory lupus neutrophils termed low-density granulocytes (LDGs) [4] 
LUPUS NEPHRITIS
The NLRP3 inflammasome has received a significant amount of attention as a contributor to lupus nephritis in murine models. Daily treatment of NZB/NZW F1 mice with epigallocatechin-3-gallate, a major bioactive polyphenol in green tea, reduced renal inflammation and suppressed upregulation of NLRP3 and activation of IL-1b and IL-18 in the kidneys of these mice. No suppression of antidsDNA antibodies or activation of T or B cells was observed in this model [32] . Signaling through many TLR receptors activates NLRP3 expression via activation of NFkB [8] , and thus acts as an important priming step for inflammasome inhibition. Recently, it has been suggested that the beneficial effects of TLR7, TLR8, and TLR9 inhibition in NZBW/F1 murine lupus models stem at least partially through blockade of NLRP3 . Blockade of high-mobility group box 1 protein (HMGB1), a danger signal that circulates on nucleosome and NET-derived complexes at higher levels in SLE [3, 39] , has also shown success in abrogating caspase-1 activation and lupus nephritis in BXSB mice [40 & ]. The inflammasome scaffold AIM2 has also been studied for its role in SLE pathogenesis. AIM2 binds cytoplasmic DNA and induces inflammasome activation through recruitment of the adaptor molecule ASC through its PYRIN domain [41] . Balb/c mice induced to develop a lupus-like syndrome by repeated injection of apoptotic DNA have elevated levels of AIM2 expression in multiple organs, which correlates with disease progression. Further, these mice have a diminished lupus-like phenotype when AIM2 is knocked down [42 & ]. Others, however, have demonstrated that inhibition of AIM2 may promote lupus pathogenesis. In mice, another interferoninducible p200 family member, p202, is upregulated in many lupus-prone strains [43, 44] . p202 negatively regulates AIM2 inflammasome activation, consequently decreasing cell death and promoting prolonged type I IFN production in response to cytosolic DNA [45 & ]. Inhibition of AIM2 results in upregulation of p202 [46] . Importantly, in T and B cells, type I IFN exposure results in suppression of AIM2 and upregulation of p202 [47] . This could thus lead to a vicious cycle of type I IFN production. Thus, the inhibition of AIM2 may be a double-edged sword with respect to lupus pathogenesis.
CUTANEOUS LUPUS
Although the inflammasome itself has not been well studied in cutaneous lupus (CLE), the inflammasome-activated cytokine IL-18 has been proposed as an important pathogenic mediator of CLE lesions.
IL-18 appears to play an important role in atopic dermatitis (reviewed in [48] ), but is less well studied in lupus. This cytokine is highly upregulated in the epidermis of CLE, but not control, skin biopsies [49] . IL-18 exposure induces upregulation of MHC class II and the chemokine CXCL10, which may be important for the recruitment and activation of inflammatory cells [50] . Additionally, keratinocytes isolated from subacute cutaneous lupus erythematosus lesions upregulate TNF-a after IL-18 stimulation, which increases keratinocyte sensitivity to apoptosis, leading to enhanced exposure of modified autoantigens. These effects of IL-18 were not noted in control keratinocytes [49] . Interestingly, ultraviolet light has been reported to activate the inflammasome in keratinocytes [51] , but whether this contributes to enhanced photosensitivity in SLE patients remains to be determined.
CARDIOVASCULAR DISEASE
SLE patients demonstrate up to a 50-fold increased risk of cardiovascular disease (CVD) [52] . The detrimental effects of type I IFNs in the vasculature of SLE patients has been proposed to be a primary pathogenic mediator of this risk (reviewed in [53] ). One mechanism in which type I IFNs impact vascular health is through their detrimental effects on growth and differentiation of endothelial progenitor cells (EPCs), which are important for vascular repair [54] . Type I IFNs repress the expression of the proangiogenic cytokine IL-1b [55] . Importantly, type I IFNs have also been shown to upregulate NLRP3, caspase-1, and IL-18 in human EPC cultures, which results in enhanced production of IL-18. IL-18, in turn, has inhibitory effects on EPC differentiation to mature endothelial cells [23] . Inhibition of caspase-1 in these cultures prevents the detrimental effects of type I IFNs [23] , and absence of functional caspase-1 also renders murine bone marrow EPC cultures resistant to the detrimental effects of pristane-induced lupus on EPC function and improves endothelial function in vivo [36
Thus, the balance of IL-1b and IL-18 production via inflammasome activation, as influenced by type I IFN exposure, may have important consequences for vascular health in SLE.
Cholesterol crystals, which accumulate in atherosclerotic plaques, are able to stimulate inflammasome activation, and this activation is required for atherosclerosis development in the LDL-receptor knockout model of atherosclerosis [14] . Interestingly, a role for complement activation in enhancing the activation of the inflammasome in response to cholesterol crystals has recently been documented [56 & ]. Whether immune-complexmediated complement activation and deposition
THE IMPORTANCE OF INFLAMMASOME-GENERATED CYTOKINES IN SYSTEMIC LUPUS ERYTHEMATOSUS
IL-18 has been postulated as important in SLE as noted above. Serum levels of this cytokine are elevated in SLE patients and correlate with disease severity, autoantibody profiles, and the presence of lupus nephritis [23, [57] [58] [59] . Moreover, IL-18 transcripts are elevated in glomeruli and tubulointerstitial compartments from patients with lupus nephritis [60] , and serum levels correlate with the severity of lupus nephritis and degree of proteinuria [61 & ]. Inhibition of IL-18 function in the murine lupus model MRL-Faslpr suggests a role for IL-18 in SLE nephritis and skin disease [62, 63] , and reductions in IL-18 transcripts have been associated with improvement in murine lupus nephritis models [64] . Unlike IL-18, increased serum levels of IL-1b are not commonly observed in SLE patients and have not been sufficiently linked to lupus pathogenesis [65] .
MODULATION OF INFLAMMASOME ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS
Therapeutic intervention for SLE patients may have modulating effects on inflammasome activity.
Hydroxychloroquine has not been shown to significantly modify the inflammatory cytokine levels in patients after 6 months of therapy [65] . However, others have shown that chloroquine is able to reduce inflammasome activation by immune complexes [24,25 && ]. Glucocorticoids induce the expression of NLRP3 and enhance its activation and IL-1b secretion by ATP in vitro [66] . In vivo, glucocorticoids may also have a positive effect on NLRP3, NLRP1, caspase-1, and IL-1b expression in SLE patients [67] . A recent study suggests that methotrexate is able to stimulate IL-1b production in a cultured monocytic cell line, but it is unclear whether this is related to induction of cell death. These findings were not able to be replicated in primary human peripheral blood mononuclear cells [68] , thus the in-vivo effects of methotrexate on inflammasome activity remain unclear. Further exploration into how treatments for SLE impact inflammasome activity are needed.
CONCLUSION
SLE is a heterogeneous disease with wide-ranging manifestations. The research discussed above suggests that the inflammasome is emerging as an important player in lupus pathogenesis (Fig. 1) . Consideration of the role of the inflammasome in further mechanistic studies of this disease is warranted. Targeting of the NLRP3 inflammasome appears to be a promising therapeutic avenue for lupus nephritis and further research is needed to This study demonstrated activation of the NLRP3 inflammasome in human monocytes by dsDNA complexes created from SLE serum. Activation was dependent on TLR9 activation of NFkB, reactive oxygen species generation, and potassium efflux. This observation suggests a mechanism by which the inflammasome may be stimulated in SLE. This is the first study to utilize a knockout model to examine the role of the inflammasome in murine lupus. Absence of caspase-1 was protective in that mice exposed to pristane did not develop chronic IFN signatures, autoantibodies or nephritis. Lack of caspase-1 was also protective for cardiovascular measures in this model. This observation solidifies the importance of the inflammasome in renal inflammation and also suggests that caspase-1 may be important in other areas of SLE pathogenesis. 
